Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | OGA | O60502 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22453894 | 0.87 | NPC1 (0.51) | ALDH1A1OGAMEN1CASP1CASP7 | |
| SCHEMBL20032194 | 0.86 | ALDH1A1 (0.51) | ALDH1A1OGAMEN1CASP1CASP7 | |
| SCHEMBL17541507 | 0.85 | UGT2B7 (0.56) | ALDH1A1OGAMEN1CASP1CASP7 | |
| SCHEMBL30644592 | 0.85 | ALDH1A1 (0.55) | ALDH1A1OGAMEN1CASP1CASP7 | |
| SCHEMBL30644683 | 0.85 | UGT2B7 (0.56) | ALDH1A1OGAMEN1CASP1CASP7 | |
| SCHEMBL17541523 | 0.85 | ALDH1A1 (0.55) | ALDH1A1OGAMEN1CASP1CASP7 | |
| SCHEMBL112749 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MEN1CASP1KMT2AHTT | |
| SCHEMBL17785872 | 0.85 | ALDH1A1 (0.53) | ALDH1A1OGAMEN1CASP1CASP7 | |
| SCHEMBL29403449 | 0.85 | ALDH1A1 (0.53) | ALDH1A1OGAMEN1CASP1CASP7 | |
| Quinoline SCHEMBL28241576 | 0.84 | ALDH1A1 (0.59) | ALDH1A1OGAMEN1CASP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4083031-B1 | QUINOLINE COMPOUND AND APPLICATION THEREOF AS FGFR4 KINASE INHIBITOR | SKYRUN PHARMA CO LTD (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2007064797-A2 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007059257-A2 | N4-PHENYL-QUINAZ0LINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070092954-A1 | Production of polyketides | ARSLANIAN ROBERT L | 2007-04-26 | — | — | US | disclosed |
| US-20070092954-A1 | Production of polyketides | ARSLANIAN ROBERT L | 2007-04-26 | — | — | US | disclosed |
| WO-2006029980-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-03-23 | — | — | WO | disclosed |
| CN-1688585-A | Antitumor analogs of lamellarins | PHARMA MAR SAU (ES) | 2005-10-26 | — | — | CN | disclosed |
| EP-0014929-B1 | DIAGNOSTIC MEANS, PROCESS FOR ITS PREPARATION AND ITS USE IN DETERMINING LEUCOCYTES IN BODY FLUIDS | Roche Diagnostics GmbH (DE) | 1982-01-06 | — | — | EP | disclosed |
| US-4299917-A | IMPREGNATION OF AN ABSORBENT CARRIER WITH A SULPHONPHTHALEIN ESTER AND AN ACTIVATOR | BOEHRINGER MANNEHEIM GMBH (DE) | 1981-11-10 | — | — | US | disclosed |
| EP-0014929-A1 | Diagnostic means, process for its preparation and its use in determining leucocytes in body fluids | Roche Diagnostics GmbH (DE) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | ALDH1A1 4342/4885OGA 2407/4885MEN1 333/4885 |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | PIGS, HRH4, GPR35 | ALDH1A1 1942/4885OGA 2941/4885MEN1 4436/4885 |
| US-20070092954-A1 | Production of polyketides | DHPS, MRPL21, FDFT1 | ALDH1A1 2923/4885OGA 2077/4885MEN1 1553/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ALDH1A1 2211/4885OGA 2660/4885MEN1 2168/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | ALDH1A1 319/4885OGA 3921/4885MEN1 3064/4885 |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | MAT1A, AMD1, MAT2B | ALDH1A1 118/4885OGA 3163/4885MEN1 525/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | ALDH1A1 959/4885OGA 3467/4885MEN1 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.